Compare Ally Financial Inc (ALLY) vs Moderna, Inc. (MRNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ally Financial Inc vs Moderna, Inc. — how do they compare? Ally Financial Inc trades at $45.64 (market cap $13.97B), while Moderna, Inc. trades at $68.05 (market cap $27.09B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Ally Financial Inc pays a 2.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ALLY | MRNA | |
|---|---|---|
Market Cap | $13.97B | $27.09B |
Sector | Financials | Health |
52-Week High | $47.25 | $81.80 |
52-Week Low | $35.96 | $22.36 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $23.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
Moderna (MRNA) trades at $68.27, down 10.83% amid a biotech sell-off, but maintains a bullish technical trend with strong moving averages. Revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B, yet recent quarterly EPS beats and pipeline expansions into oncology and flu vaccines fuel optimism. The stock remains volatile, with a consensus price target of $49.00 below the current price, reflecting mixed analyst sentiment.
The outlook hinges on pipeline execution, with EU RSV vaccine contracts and FDA decisions offering upside, but high cash burn and competitive pressures pose risks. Investors face a trade-off between growth potential and profitability challenges, with the stock's 70% monthly surge testing sustainability near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
